A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes. It also reduced the ...

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama/Getty The Food and Drug Administration has approved Ozempic to reduce the ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s diabetes-cum-weight loss drug Ozempic for patients with both chronic kidney disease and diabetes. This came after clinical trials ...

By Dani Blum The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both Type 2 diabetes and chronic kidney disease.

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news ...